Michael Bachmann

ORCID: 0000-0002-8029-5755
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • CAR-T cell therapy research
  • Monoclonal and Polyclonal Antibodies Research
  • Immunotherapy and Immune Responses
  • Immune Cell Function and Interaction
  • T-cell and B-cell Immunology
  • Radiopharmaceutical Chemistry and Applications
  • Nanowire Synthesis and Applications
  • RNA Research and Splicing
  • RNA and protein synthesis mechanisms
  • Cancer Immunotherapy and Biomarkers
  • Glycosylation and Glycoproteins Research
  • RNA Interference and Gene Delivery
  • Virus-based gene therapy research
  • Systemic Lupus Erythematosus Research
  • Viral Infectious Diseases and Gene Expression in Insects
  • Cell Adhesion Molecules Research
  • Nuclear Structure and Function
  • Advancements in Semiconductor Devices and Circuit Design
  • Prostate Cancer Treatment and Research
  • Medical Imaging Techniques and Applications
  • Advanced biosensing and bioanalysis techniques
  • Viral Infections and Immunology Research
  • Salivary Gland Disorders and Functions
  • German Literature and Culture Studies
  • RNA regulation and disease

Helmholtz-Zentrum Dresden-Rossendorf
2016-2025

University Hospital Carl Gustav Carus
2016-2025

TU Dresden
2016-2025

National Center for Tumor Diseases
2016-2025

German Cancer Research Center
2016-2025

Heidelberg University
2016-2025

Deutschen Konsortium für Translationale Krebsforschung
2016-2025

National Institutes of Health
2024

Institute of Neuroimmunology of the Slovak Academy of Sciences
2024

Eunice Kennedy Shriver National Institute of Child Health and Human Development
2024

Owing to the more recent positive results with anti-CD33 immunotoxin gemtuzumab ozogamicin, therapy against acute myeloid leukemias (AMLs) targeting CD33 holds many promises. Here, and CD123 expression on AML blasts was studied by flow cytometry in a cohort of 319 patients detailed information French-American-British/World Health Organization (FAB/WHO) classification, cytogenetics molecular aberrations. AMLs 87.8% express would therefore be targetable therapies. Additionally, 9.4% without...

10.1038/bcj.2014.39 article EN cc-by-nc-nd Blood Cancer Journal 2014-06-13

Abstract The adoptive transfer of CD19-specific chimeric antigen receptor engineered T cells (CAR cells) resulted in encouraging clinical trials indolent B-cell malignancies. However, they also show the limitations this fascinating technology: CAR can lead to even life-threatening off-tumor, on-target side effects if crossreact with healthy tissues. Here, we describe a novel modular universal platform technology termed UniCAR that reduces risk by rapid and reversible control T-cell...

10.1038/bcj.2016.61 article EN cc-by Blood Cancer Journal 2016-08-12

Abstract NK cells are emerging as new effectors for immunotherapy of cancer. In particular, the genetic engraftment chimeric Ag receptors (CARs) in is a promising strategy to redirect otherwise cell–resistant tumor cells. On basis DNAX-activation protein 12 (DAP12), signaling adaptor molecule involved signal transduction activating cell receptors, we generated type CAR targeting prostate stem (PSCA). We demonstrate this article that CAR, designated anti–PSCA-DAP12, consisting DAP12 fused...

10.4049/jimmunol.1400330 article EN The Journal of Immunology 2015-03-05

The human Wilms' tumor gene WT1 encodes a putative transcription factor implicated in tumorigenesis and specifying normal urogenital development. We have studied the distribution of protein mRNA using immunohistochemistry situ hybridization. Monoclonal antibodies were raised against peptide specific to first alternative splice site WT1. Two specifically reacted on Western blot this isoform. Immunofluorescence localized podocytes during mesonephric metanephric In hybridization revealed...

10.1242/dev.119.4.1329 article EN Development 1993-12-01

Ajuga reptans is a frost-hardy, perennial labiate that known for its high content of raffinose family oligosaccharide(s) (RFO). Seasonal variations in soluble nonstructural carbohydrate levels above-ground parts showed the RFO were by far most predominant components throughout whole year. lowest summer (75 mg/g fresh weight) and highest fall/winter (200 weight), whereas sucrose starch only minor components. Cold treatment (14 d at 10/3[deg]C, day/night) plants precultivated under warm...

10.1104/pp.105.4.1335 article EN PLANT PHYSIOLOGY 1994-08-01

Prognosis for patients suffering from malignant glioma has not substantially improved. Specific immunotherapy as a novel treatment concept critically depends on target antigens, which are highly overexpressed in the majority of gliomas, but number such antigens is still very limited. SOX2 was identified by screening an expression database transcripts that glioma, display minimal normal tissues. Expression mRNA further investigated tumour and tissues real-time PCR. Compared to cDNA pooled...

10.1038/sj.bjc.6603696 article EN cc-by-nc-sa British Journal of Cancer 2007-03-20

Spinach leaf NADH:nitrate reductase (NR) responds to light/dark signals and photosynthetic activity in part as a result of rapid regulation by reversible protein phosphorylation. We have identified the major regulatory phosphorylation site Ser-543, which is located hinge 1 region connecting cytochrome b domain with molybdenum-pterin cofactor binding NR, using recombinant NR fragments containing or lacking sequence. Studies partial reactions indicated that block electron flow caused also...

10.1105/tpc.8.3.505 article EN The Plant Cell 1996-03-01

Sjögren's syndrome is a chronic autoimmune disease affecting the lacrimal glands and other epithelia. It has been suggested that acinar cells of provoke local responses, leading to when they begin expressing major histocompatibility complex (MHC) class II molecules. We used isopycnic centrifugation phase partitioning resolve compartments participate in traffic between basolateral membranes endomembrane system test hypothesis MHC molecules enter contain potential autoantigens, i.e., La/SSB,...

10.1152/ajpcell.1999.277.5.c994 article EN AJP Cell Physiology 1999-11-01

// Anja Feldmann 1, * , Claudia Arndt Ralf Bergmann Simon Loff 2, 3, Marc Cartellieri 4, Dominik Bachmann ** Roberta Aliperta Mirjam Hetzenecker Florian Ludwig Susann Albert Pauline Ziller-Walter Alexandra Kegler Stefanie Koristka Sebastian Gärtner Schmitz 5, 7, 8 Armin Ehninger 3 Gerhard 6, Jens Pietzsch 9 Jörg Steinbach 8, and Michael 1 Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Institute of Radiopharmaceutical Cancer Research, Dresden, Germany 2 UniversityCancerCenter (UCC)...

10.18632/oncotarget.15572 article EN Oncotarget 2017-02-21

Recent treatments of leukemias with chimeric antigen receptor (CAR) expressing T cells underline their impressive therapeutic potential. However, once adoptively transferred into patients, there is little scope left to shut them down after elimination tumor or in case adverse side effects occur. This becomes special relevance if they are directed against commonly expressed associated antigens (TAAs) such as receptors the ErbB family. To overcome this limitation, we recently established a...

10.1080/2162402x.2017.1287246 article EN OncoImmunology 2017-02-06

Plasmacytoid dendritic cells (pDCs) play a key role in the induction and maintenance of antitumor immunity. Conversely, they can act as tolerogenic DCs by inhibiting tumor-directed immune responses. Therefore, pDCs may profoundly influence tumor progression. To gain novel insights into colon cancer, we investigated frequency clinical relevance primary tissues from patients with cancer different clinicopathological characteristics.Immunohistochemical stainings were performed to explore...

10.1136/jitc-2020-001813 article EN cc-by-nc Journal for ImmunoTherapy of Cancer 2021-03-01

Chimeric antigen receptor T cells (CAR-T) targeting CD19 or B cell maturation (BCMA) are highly effective against malignancies. However, application of CAR-T to less differentially expressed targets remains a challenge due lack tumor-specific antigens and controllability. CD123, promising leukemia target, is not only by leukemic leukemia-initiating cells, but also myeloid, hematopoietic progenitor, certain endothelial cells. Thus, lacking fine-tuned control mechanisms pose high toxicity...

10.1016/j.omto.2020.04.009 article EN cc-by Molecular Therapy — Oncolytics 2020-04-29

Antigen-specific redirection of immune effector cells with chimeric antigen receptors (CARs) demonstrated high therapeutic potential for targeting cancers different origins. Beside CAR-T cells, natural killer (NK) represent promising alternative effectors that can be combined CAR technology. Unlike T primary NK and the cell line NK-92 applied as allogeneic off-the-shelf products a reduced risk toxicities. We previously established modular universal (UniCAR) platform which consists...

10.1038/s41598-020-59082-4 article EN cc-by Scientific Reports 2020-02-07

Detection of antigens and antibodies (Abs) is great importance in determining the infection immunity status population, as they are key parameters guiding handling pandemics. Current point-of-care (POC) devices a convenient option for rapid screening; however, their sensitivity requires further improvement. We present an interdigitated gold nanowire-based impedance nanobiosensor to detect COVID-19-associated (receptor-binding domain S1 protein SARS-CoV-2 virus) respective Abs appearing...

10.1021/acssensors.2c01686 article EN cc-by ACS Sensors 2023-02-10
Coming Soon ...